United States-based ANI Pharmaceuticals, Incorporated (Nasdaq:ANIP) has launched its Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg, it was reported on Tuesday.
The product is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Patrick Walsh, ANI's interim president and CEO, said, 'This is our sixth generic product launch in 2020. The launch represents an important milestone for ANI in the integration of our Oakville, Canada manufacturing site, acquired in August 2018. Mexiletine is the first new ANI product launch from the Oakville site. I congratulate the team in Oakville on achieving this milestone; we look forward to additional ANI product launches from this plant in the future.'
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval